GlassScriptPhysician profile
Kenneth J Wolok
NPI 1194715557
$12,495.45
in general payments reported to CMS, 2019-2025
48 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $871 · 2021: $1,653 · 2022: $1,935 · 2023: $1,801 · 2024: $2,147 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,107.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,401.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,241.89 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $923.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $907.19 | 2019-2025 | Jardiance |
| Abbvie INC. | $831.28 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $793.74 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $624.21 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $439.81 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Amarin Pharma, INC. | $411.49 | 2019-2023 | |
| Esperion Therapeutics, INC. | $402.29 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $400.01 | 2019-2024 | |
| Astellas Pharma US INC | $328.81 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $304.18 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $239.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $217.95 | 2023-2025 | Rexulti, Nuedexta |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $216.05 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $172.71 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $171.46 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $144.81 | 2023-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $142.64 | 2021-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $126.29 | 2019-2023 | |
| Lundbeck LLC | $123.04 | 2024-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $98.17 | 2021-2023 | |
| Corcept Therapeutics | $88.42 | 2025 | Korlym |
| Exact Sciences Corporation | $62.89 | 2023-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $61.27 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $59.26 | 2021-2022 | |
| Alk-Abello, INC | $54.87 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Biohaven Pharmaceuticals, INC. | $49.98 | 2021 | |
| Boston Scientific Corporation | $41.06 | 2023-2024 | |
| Allergan, INC. | $38.80 | 2019-2020 | |
| Medtronic, INC. | $36.84 | 2025 | Inceptiv |
| Intra-Sana Laboratories | $34.80 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Mylan Specialty L.P. | $34.07 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.17 | 2025 | Caplyta |
| Eisai INC. | $27.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.96 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.66 | 2025 | Edarbi |
| Sanofi Pasteur INC. | $20.50 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.88 | 2025 | Xifaxan |
| Solta Medical, A Division of Bausch Health US, LLC | $19.52 | 2025 | Clear+Brilliant |
| Seqirus USA INC | $15.58 | 2024 | Flucelvax, Fluad |
| Aimmune Therapeutics, INC. | $15.40 | 2024 | |
| Validus Pharmaceuticals LLC | $14.83 | 2025 | Equetro, Raldesy |
| Ibsa Pharma INC. | $14.30 | 2023 | Tirosint, Licart |
| Urovant Sciences INC | $14.04 | 2021 | |
| Currax Pharmaceuticals LLC | $13.06 | 2023 | Contrave |
| E.R. Squibb & Sons, L.L.C. | $12.76 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wolok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.